Biotelemetry 10-Q 1 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 29, 2014
Document and Entity Information	'	'
Entity Registrant Name	'BioTelemetry, Inc.	'
Entity Central Index Key	'0001574774	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	26,458,841
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$13,546	$22,151
Accounts receivable, net of allowance for doubtful accounts of $9,801 and $7,555, at June 30, 2014 and December 31, 2013, respectively	15,702	11,437
Other receivables, net of allowance for doubtful accounts of $259 and $85 at June 30, 2014 and December 31, 2013, respectively	7,877	5,680
Inventory	2,970	2,554
Prepaid expenses and other current assets	1,670	2,433
Total current assets	41,765	44,255
Property and equipment, net	29,084	18,779
Intangible assets, net	16,963	7,312
Goodwill	29,503	16,469
Other assets	1,094	731
Total assets	118,409	87,546
Current liabilities:	'	'
Accounts payable	14,439	8,718
Accrued liabilities	17,478	8,190
Current portion of capital leases	554	187
Current portion of long term debt	450	'
Deferred revenue	2,903	1,945
Total current liabilities	35,824	19,040
Long term debt	17,186	'
Deferred tax liability	1,258	767
Long term portion of capital leases	589	469
Deferred rent	852	441
Total liabilities	55,709	20,717
Shareholders' equity:	'	'
Common stock, $0.001 par value; 200,000,000 shares authorized; 26,421,886 and 25,812,754 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	26	26
Paid-in capital	264,578	260,597
Accumulated deficit	-201,904	-193,794
Total stockholders' equity	62,700	66,829
Total liabilities and stockholders' equity	$118,409	$87,546

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
CONSOLIDATED BALANCE SHEETS	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$9,801	$7,555
Other receivable, allowance for doubtful accounts (in dollars)	$259	$85
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	26,421,886	25,812,754
Common stock, shares outstanding	26,421,886	25,812,754

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Patient service	$34,160	$24,910	$63,454	$49,615
Research services	5,245	5,252	10,085	10,124
Product	3,245	1,942	6,273	4,783
Total revenues	42,650	32,104	79,812	64,522
Cost of revenues:	'	'	'	'
Patient services	14,842	8,827	25,968	17,591
Research services	2,725	2,769	5,481	5,507
Product	1,470	1,012	3,106	2,383
Total cost of revenues	19,037	12,608	34,555	25,481
Gross profit	23,613	19,496	45,257	39,041
Operating expenses:	'	'	'	'
General and administrative	11,139	9,077	21,911	18,605
Sales and marketing	7,172	6,267	14,612	13,029
Bad debt expense	2,745	1,967	5,104	4,434
Research and development	1,958	1,882	3,747	3,502
Integration, restructuring and other charges	1,000	2,541	3,980	3,743
Total expenses	24,014	21,734	49,354	43,313
Loss from operations	-401	-2,238	-4,097	-4,272
Interest and other loss, net	-3,587	-61	-6,858	-114
Loss before income taxes	-3,988	-2,299	-10,955	-4,386
Benefit from income taxes	'	'	2,845	'
Net loss and comprehensive loss	($3,988)	($2,299)	($8,110)	($4,386)
Net loss per common share:	'	'	'	'
Basic and diluted (in dollars per share)	($0.15)	($0.09)	($0.31)	($0.17)
Weighted average number of common shares outstanding:	'	'	'	'
Basic and diluted (in shares)	26,434,047	25,537,358	26,272,436	25,370,164

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net loss	($8,110)	($4,386)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Provision for doubtful accounts	5,104	4,434
Depreciation	4,436	4,551
Stock-based compensation	1,968	1,711
Amortization of intangibles	1,559	1,193
Deferred income tax benefit	-2,869	'
Increase (decrease) in deferred rent	411	-172
Changes in operating assets and liabilities:	'	'
Accounts receivable	-7,585	-3,163
Inventory	-104	-789
Prepaid expenses and other assets	688	-1,724
Accounts payable	1,262	1,586
Accrued and other liabilities	7,109	921
Net cash provided by operating activities	3,869	4,162
Investing activities	'	'
Acquisition of business, net of cash acquired	-14,100	'
Purchases of property and equipment	-7,610	-3,425
Net cash used in investing activities	-21,710	-3,425
Financing activities	'	'
Proceeds from the exercise of employee stock options and employee stock purchase plan contributions	458	271
Issuance of long-term debt	17,830	'
Repayment of long-term debt	-8,798	'
Principal payments on capital lease obligations	-254	'
Net cash provided by financing activities	9,236	271
Net (decrease) increase in cash and cash equivalents	-8,605	1,008
Cash and cash equivalents - beginning of period	22,151	18,298
Cash and cash equivalents - end of period	13,546	19,306
Supplemental disclosure of cash flow information	'	'
Cash paid for interest	370	'
Cash paid for taxes	$134	$105

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	1.   Summary of Significant Accounting Policies
	Unaudited Interim Financial Data
	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and the requirements of Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations and cash flows.  In the opinion of management, these consolidated financial statements reflect all adjustments which are of a normal recurring nature and necessary for a fair presentation of BioTelemetry, Inc.’s (the “Company” or “BioTelemetry”) financial position as of June 30, 2014 and December 31, 2013, the results of operations for the three and six months ended June 30, 2014 and 2013, and cash flows for the six months ended June 30, 2014 and 2013.  The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2014 and 2013 are unaudited. The results for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for any future period.
	Net Loss
	The Company computes net loss per share in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 260, Earnings Per Share.  The following summarizes the potential outstanding common stock of the Company at June 30, 2014 and 2013:
		June 30, 2014		June 30, 2013
	Employee stock purchase plan estimated share options outstanding	88,094		50,477
	Common stock options and restricted stock units outstanding	4,322,496		4,129,523
	Common stock options and restricted stock units available for grant	3,105,541		2,429,098
	Common stock	26,421,886		25,549,762
	Total	33,938,017		32,158,860
	Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options and warrants, as applicable.
	The following table presents the calculation of basic and diluted net loss per share:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
		(in thousands, except share and per share amounts)
	Numerator:
	Net loss	$	(3,988	)	$	(2,299	)	$	(8,110	)	$	(4,386	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share	26,434,047			25,537,358			26,272,436			25,370,164
	Basic and diluted net loss per share	$	(0.15	)	$	(0.09	)	$	(0.31	)	$	(0.17	)
	If the outstanding vested options or restricted stock units were exercised or converted into common stock, the result would be anti-dilutive for the three and six months ended June 30, 2014 and 2013. Accordingly, basic and diluted net loss per share are the same for the three and six months ended June 30, 2014 and 2013.
	Fair Value of Financial Instruments
	The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For our long-term debt, based on the borrowing rates currently available to us, the carrying value also approximates fair value as of June 30, 2014 (classified as Level 2).  We did not have any Level 3 assets or liabilities for the periods ended June 30, 2014 and December 31, 2013.
	Cash and Cash Equivalents
	Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk.
	Accounts Receivable
	Accounts receivable related to the Patient Services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. The Company records allowance for doubtful accounts based on the aging of receivables using historical payor specific data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the healthcare industry and third party reimbursement, it is possible that the Company’s estimates of collectability could change, which could have a material impact on the Company’s operations and cash flows.
	Accounts receivable related to the Product and Research Services segments are recorded at the time revenue is recognized, or when the services or products are billable, net of discounts. The Company estimates allowance for doubtful accounts on a specific account basis, and considers several factors in its analysis including customer specific information and aging of the account.
	The Company writes off receivables when the likelihood for collection is remote and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect.  The Company performs write-offs on a monthly basis.  In the Patient Services segment, the Company wrote off $2,851 and $4,637 of receivables for the six months ended June 30, 2014 and 2013, respectively.  The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts.  There were no material write-offs in the Product and Research Services segments.  For the three and six months ended June 30, 2014, the Company recorded bad debt expense of $2,745 and $5,104, respectively.  For the three and six months ended June 30, 2013, the Company recorded bad debt expense of $1,967 and $4,434, respectively.
	Inventory
	Inventory consists of the following:
		June 30,			December 31,
		2014			2013
	Raw materials and supplies	$	2,686		$	2,404
	Finished goods	284			150
	Total inventories	$	2,970		$	2,554
	Inventories, which include purchased parts, materials, direct labor and applied manufacturing overhead, are stated at the lower of cost or net realizable value, with cost determined by use of the first-in, first-out method.
	Goodwill
	Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units’ goodwill. If the carrying value of the reporting units’ goodwill exceeds its implied fair value, an impairment loss equal to the difference is recorded.
	For the purpose of performing its goodwill impairment analysis, the Company considers its business to be comprised of three reporting units: Patient Services, Product and Research Services. The Company calculates the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes the Company’s market data as well as market data from publicly traded companies that are similar to the Company. There are inherent uncertainties related to these factors and the judgment applied in the analysis. The Company believes that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of its reporting units.
	Stock-Based Compensation
	ASC 718, Compensation — Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measure the cost of equity-based service awards based on the grant-date fair value of the award and recognize the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measure the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. The Company accounts for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.
	As a result of stock-based compensation expense incurred, the Company’s loss before income taxes was increased by $965 and $1,968, respectively, during the three and six months ended June 30, 2014.  As a result of stock-based compensation expense incurred, the Company’s loss before income taxes was increased by $1,011 and $1,711 during the three and six months ended June 30, 2013, respectively.  For the three and six months ended June 30, 2014, the impact of stock-based compensation expense on basic and diluted earnings per share was $(0.04) and $(0.07).  For the three and six months ended June 30, 2013, the impact of stock-based compensation expense on basic and diluted earnings per share was $(0.04) and $(0.07).
	The Company estimates the fair value of its share-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of the Company’s stock and the expected term of the award. For the six months ended June 30, 2014 and 2013, the Company based the estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that stock-based awards granted are expected to be outstanding. Other assumptions used in the Black-Scholes option valuation model include the risk-free interest rate and expected dividend yield. The risk-free interest rate for periods pertaining to the contractual life of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.
	The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted using the following weighted average assumptions:
		Six months Ended
		June 30,
		2014		2013
	Expected dividend yield	0	%	0	%
	Expected volatility	62	%	60	%
	Risk-free interest rate	1.85	%	1.28	%
	Expected life	6.46		6.75
	Based on the Company’s historical experience of options that cancel before becoming fully vested, the Company has assumed an annualized forfeiture rate of 15% for all options. Under the true-up provision of ASC 718, the Company will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
	Based on the above assumptions, the per share weighted average fair value of the options granted under the stock option plan for the six months ended June 30, 2014 and 2013 was $4.96 and $1.47, respectively.
	The following table summarizes activity under all stock award plans from December 31, 2013 through June 30, 2014:
				Options Outstanding
		Shares				Weighted
		Available		Number		Average
		for Grant		of Shares		Exercise Price
	Balance — December 31, 2013	2,404,498		3,993,590		$	5.25
	Additional options available for grant	1,291,200		—		—
Granted	(623,650	)	623,650		8.38
Canceled	68,044		(68,044	)	3.59
Exercised	—		(192,580	)	4.52
Balance — March 31, 2014	3,140,092		4,356,616		5.78
Granted	(125,985	)	125,985		8.2
Canceled	91,434		(91,434	)	4.51
Exercised	—		(68,671	)	4.55
Balance — June 30, 2014	3,105,541		4,322,496		$	5.91
The Employee Stock Option (ESOP) Plans have an automatic increase in the shares available for grant every January the plans are active. The increase in the shares available for grant under the ESOP plan is equal to 4% of the total shares outstanding at December 31, 2013.
Additional information regarding options outstanding is as follows:
	June 30, 2014			June 30, 2013
Range of exercise prices (per option)	$	0.70 - $31.18		$	0.70 - $31.18
Weighted average remaining contractual life (years)	7.31			7.77
Employee Stock Purchase Plan
In 2014, 169,610 shares were purchased in accordance with the Employee Stock Purchase Plan (ESPP). Net proceeds to the Company from the issuance of shares of common stock under the ESPP for the six months ended June 30, 2014 were $397. In January 2014, the number of shares available for grant was increased by 258,240, per the ESPP documents. At June 30, 2014, approximately 606,086 shares remain available for purchase under the ESPP.
Recent Accounting Pronouncements
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition.  The new standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which the company expects to receive in exchange for those goods or services.  The standard also requires new, expanded disclosures regarding revenue recognition and is effective for the annual reporting periods beginning after December 15, 2016.  The Company is currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.

Business_Combination

Business Combination	6 Months Ended
	Jun. 30, 2014
Business Combination	'
Business Combination	'
	2.   Business Combination
	Mednet Healthcare Technologies, Inc
	On January 31, 2014, the Company, through its wholly owned subsidiary CardioNet, LLC (“CardioNet”), acquired Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc., and Universal Medical Laboratory, Inc. (together, “Mednet”).  Mednet provides cardiac monitoring services and is an original equipment manufacturer of cardiac monitoring devices.  The acquisition gave the Company access to established customer relationships.  Upon the closing of the transaction, the Company acquired all of the issued and outstanding capital stock, and Mednet became a wholly-owned subsidiary of the Company.  The Company paid $5,500 in cash at closing and 96,649 shares of the Company’s common stock, valued at $705 at closing.  In addition, as a result of the acquisition, the Company assumed indebtedness from Mednet in the aggregate amount of $9,720, including interest.  The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition.
	The amounts below represent the preliminary fair value estimates as of June 30, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. The primary areas of those preliminary estimates that were not yet finalized related to certain tangible assets and liabilities acquired, as well as identifiable intangible assets. The Company expects to complete the accounting for the Mednet acquisition within a year of the acquisition date.
	Fair value of assets acquired:
	Cash and cash equivalents	$	(199	)
	Accounts receivable	3,879
	Prepaid expenses and other current assets	355
	Property and equipment	4,400
	Goodwill	9,261
	Intangible assets	8,490
	Other assets	73
	Total assets acquired	26,259
	Liabilities assumed:
	Accounts payable	5,927
	Accrued expenses	994
	Other liabilities	3,413
	Long-term debt, capital leases, note payable and related interest	9,720
	Total liabilities assumed	20,054
	Net assets acquired	$	6,205
	While the purchase price allocation has not been finalized, the estimated allocation of intangible assets is comprised of the following:
		Estimated		Fair Value
		Useful Life
		(Years)
	Customer relationships	13		$	5,800
	Internally Developed Software	5		1,600
	Covenants not to compete	5		390
	Indefinite-lived trade name			700
	Total intangible assets			$	8,490
	Goodwill recorded in connection with this acquisition is attributable to the assembled workforce and synergies expected to arise from cost savings opportunities.  All of the recorded goodwill is included in the Patient Services segment.
	The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of January 31, 2014. The pro forma information presented below does not include anticipated synergies or certain other expected benefits of the acquisition and should not be used as a predictive measure of our future results of operations. Mednet contributed $6,164 and $10,636 in revenue for the three and six months ended June 30, 2014.
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Revenue	$	42,650		$	38,831		$	83,310		$	78,656
	Net Loss	$	(3,988	)	$	(3,396	)	$	(6,331	)	$	(3,155	)
	Net loss per common share:
	Basic and Diluted	$	(0.15	)	$	(0.13	)	$	(0.24	)	$	(0.12	)
	Weighted average number of shares:
	Basic	26,434,047			26,815,245			26,272,436			25,634,007
	Biomedical Systems Corporation
	On April 3, 2014, the Company, through its wholly-owned subsidiary CardioNet, LLC, completed the acquisition of substantially all of the assets of Biomedical Systems Corporation’s (“BMS”) cardiac event monitoring, Holter monitoring and mobile telemetry monitoring services.  The acquisition gave the Company access to internally developed Holter software and to established customer relationships.  The Company paid $8,000 in cash at closing and 62,859 shares of the Company’s common stock, valued at $650 at closing.  The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition.
	The amounts below represent the preliminary fair value estimates as of June 30, 2014 and are subject to subsequent adjustment as additional information is obtained during the measurement period. The primary areas of those preliminary estimates that were not yet finalized related to certain tangible assets and identifiable intangible assets. The Company will complete the accounting for the BMS acquisition within a year of the acquisition date.
	Fair value of assets acquired:
	Property and equipment	$	2,731
	Goodwill	3,559
	Intangible assets	2,360
	Net assets acquired	$	8,650
	While the purchase price allocation has not been finalized, the estimated allocation of intangible assets is comprised of the following:
		Estimated		Fair Value
		Useful Life
		(Years)
	Customer relationships	15		$	2,100
	Covenants not to compete	7		260
	Total intangible assets			$	2,360
	Goodwill recorded in connection with this acquisition is attributable to synergies expected to arise from cost savings opportunities.  All of the recorded goodwill is included in the Patient Services segment.
	Other Acquisitions
	On June 3, 2014, the Company, through its wholly owned subsidiary CardioCore Lab, LLC (“CardioCore”), acquired the assets of RadCore Lab, LLC (“RadCore”), an imaging core lab serving the biopharmaceutical and medical device research market. This acquisition broadens the Companys offerings and adds new oncology, musculoskeletal and neurological imaging capabilities, supported by a state-of-the-art, cloud-based analysis platform. The Company paid $400 in cash at closing and 22,513 shares of the Company’s common stock, valued at $200 at closing.  While this acquisition provides growth potential, the acquisition of RadCore did not have a material effect on our financial condition, results of operations or cash flows.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets	'
Goodwill and Intangible Assets	'
	3. Goodwill and Intangible Assets
	Goodwill was recognized at the time of the Company’s acquisitions. The carrying amounts of goodwill as of June 30, 2014 and December 31, 2013 are $29,503 and $16,469, respectively.
	The changes in the carrying amounts of goodwill by segment were as follows:
		Reporting Segment
		Patient			Research			Product		Total
		Services			Services
	Balance at December 31, 2013	$	1,577		$	11,735		$	3,157	$	16,469
	Goodwill acquired during the year	12,820			214			—		13,034
	Balance at June 30, 2014	$	14,397		$	11,949		$	3,157	$	29,503
	At December 31, 2013, the Company performed its required annual impairment test of goodwill. Based on this impairment test, the Company determined that none of the reporting unit’s goodwill was impaired.
	The gross carrying amounts and accumulated amortization of the Company’s intangible assets as of June 30, 2014 and December 31, 2013 are as follows:
		Estimated		June 30,			December 31,
		Useful Life		2014			2013
		(Years)
	Customer relationships	5 - 15		$	10,000		$	2,100
	Proprietary technology	5-Mar		5,600			4,000
	Signed backlog	1 - 4		3,160			2,800
	Unsigned backlog	4		600			600
	Covenants not to compete	7-May		1,010			360
	Total intangible assets, gross			20,370			9,860
	Customer relationships accumulated amortization			(1,111		)	(722		)
	Proprietary technology accumulated amortization			(2,649		)	(1,902		)
	Signed backlog accumulated amortization			(1,671		)	(1,400		)
	Unsigned backlog accumulated amortization			(275		)	(200		)
	Covenants not to compete accumulated amortization			(201		)	(124		)
	Total accumulated amortization			(5,907		)	(4,348		)
	Indefinite-lived trade name			2,500			1,800
	Total intangible assets, net			$	16,963		$	7,312
	The estimated amortization expense for the next five years is summarized as follows at June 30, 2014:
	Remainder of 2014	$	1,725
	2015	3,095
	2016	1,999
	2017	1,295
	2018	1,156
	2019	791
	Thereafter	4,402
	Total	$	14,463
	Amortization expense for the three months ended June 30, 2014 and 2013 was $871 and $574, respectively, and amortization expense for the six months ended June 30, 2014 and 2013 was $1,559 and $1,193, respectively.  The increase in amortization expense is primarily driven by the current year acquisitions.

Integration_Restructuring_and_

Integration, Restructuring and Other Charges	6 Months Ended
	Jun. 30, 2014
Integration, Restructuring and Other Charges	'
Integration, Restructuring and Other Charges	'
	4.              Integration, Restructuring and Other Charges
	The Company accounts for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and records the expenses in Integration, restructuring and other charges in its statement of operations, and records the related accrual in the Accrued expenses line of its balance sheet.
	For the three and six months ended June 30, 2014 and 2013, the Company incurred expenses related to restructuring, integration and other activities. These expenses were primarily a result of the Company’s recent patent litigation, the Civil Investigative Demand, as well as the activities surrounding the Company’s acquisitions. A summary of these expenses is as follows:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Legal fees	$	285	$	2,144	$	2,734	$	2,682
	Severance and employee related costs	593		187		755		740
	Professional fees	122		210		491		321
	Total	$	1,000	$	2,541	$	3,980	$	3,743

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes	'
Income Taxes	'
	5.              Income Taxes
	The income tax provision for interim periods is determined using an estimated annual effective tax rate adjusted for discrete items, if any, which are taken into account in the quarterly period in which they occur. The Company reviews and updates its estimated annual effective tax rate each quarter. For the six months ended June 30, 2014, the Company’s estimated annual effective tax rate was zero. The Company recorded $2,869 of a tax benefit for the six months ended June 30, 2014 related to the Mednet acquisition that occurred in January 2014.
	As of June 30, 2014, in accordance with ASC 740, the Company maintained a full valuation allowance against net deferred tax assets, with exception to the deferred tax liability recorded for indefinite lived intangibles. The Company will continue to maintain a full valuation allowance until such time it can reasonably estimate the probability of realizing a benefit from the deferred tax assets.

Credit_Agreement

Credit Agreement	6 Months Ended
	Jun. 30, 2014
Credit Agreement	'
Credit Agreement	'
	6.              Credit Agreement
	On August 29, 2012, the Company entered into a Credit and Security Agreement (“Credit Agreement”) with MidCap Financial, LLC to provide revolving loan borrowings with a loan commitment of up to $15,000, with an option by the Company to increase to a maximum loan commitment of $30,000. Interest on borrowings under the Credit Agreement is based on the London Interbank Offered Rate (“LIBOR”) plus an applicable margin of 4.75%. An unused line fee of 0.50% per annum is payable on any unused line balance, determined as the total loan commitment of $15,000 minus the average daily balance of the sum of the revolving loan borrowings outstanding during the preceding month. Furthermore, if the Company terminates the agreement at any point prior to the loan expiration date, the Company will incur a loan origination fee of 1.00% of the loan commitment due immediately preceding the termination. The Credit Agreement is secured by the Company’s personal property, inventory and other assets and expires in August 2016.  The Company withdrew $8,000 on April 3, 2014 to fund the BMS acquisition.  As of June 30, 2014, the Company’s outstanding balance on the credit agreement was $8,000.
	On February 21, 2014, the Company entered into a Credit and Security Agreement (the “Credit Agreement”) with The Bancorp Bank for an aggregate amount of $9,830.  The proceeds were used to pay off the assumed debt of $8,563 associated with the Mednet acquisition. The Loans bear interest at an annual rate of 3.25% until March 1, 2019, and thereafter will bear interest at an annual rate equal to the greater of (1) 3.25% or (2) the prime rate as published in the “Money Rates” section of The Wall Street Journal or the highest prime rate if more than one is published.  Beginning April 1, 2014, the principal amount of the Loans will be repaid, on a monthly basis, in installments of $38, plus accrued interest, until April 1, 2019, when the principal amount of the Loans will be repaid, on a monthly basis, in installments of $75, plus accrued interest, until paid in full on or before March 1, 2024 or such earlier date upon an acceleration of the Loans by Lenders upon an event of default or termination of the Borrowers.  As of June 30, 2014, the Company’s outstanding balance on the credit agreement was $9,636.

Segment_Information

Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Information	'
Segment Information	'
	7.              Segment Information
	The Company operates under three segments: Patient Services, Product and Research Services. The Patient Services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry™ (“MCOT™”), wEvent, event, Holter and Pacemaker monitoring services, as well as INR services in a healthcare setting.  INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term warfarin therapy.  The Product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals.  The Research Services segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials..  Intercompany revenue relating to the manufacturing of devices by the Product segment for the other segments is included on the intersegment revenue line.
	Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income. Any remaining expenses including research and development costs as well as the elimination of costs associated with intercompany revenue are included in Corporate and Other. Also included in Corporate and Other is the Department of Justice settlement, as well as net financing expenses and other income which consist principally of interest expense and other financing expenses less interest income.  The Company does not allocate assets to the individual segments.  Mednet and BMS are primarily included in the Patient Services segment; with the manufacturing and product sales parts of the businesses being included in the Product segment.  Radcore is included in the Research Services segment.
	For the three months ended:
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2014
	Revenues	$	34,160	$	5,245	$	3,245	—		$	42,650
	Intersegment revenues	—		—		1,778		(1,778	)	—
	Income (loss) before income taxes	6,472		233		1,512		(12,205	)	(3,988		)
	Depreciation and amortization	2,124		910		130		78		3,242
	Capital expenditures	3,442		271		38		—		3,751
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2013
	Revenues	$	24,910	$	5,252	$	1,942	—		$	32,104
	Intersegment revenues	—		—		1,671		(1,671	)	—
	Income (loss) before income taxes	6,675		328		1,470		(10,772	)	(2,299		)
	Depreciation and amortization	1,463		848		139		286		2,736
	Capital expenditures	1,190		377		19		—		1,586
	For the six months ended:
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2014
	Revenues	$	63,454	$	10,085	$	6,273	—		$	79,812
	Intersegment revenues	—		—		4,815		(4,815	)	—
	Income (loss) before income taxes	11,978		19		3,590		(26,542	)	(10,955		)
	Depreciation and amortization	3,695		1,794		263		243		5,995
	Capital expenditures	6,843		675		92		—		7,610
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2013
	Revenues	$	49,615	$	10,124	$	4,783	—		$	64,522
	Intersegment revenues	—		—		2,744		(2,744	)	—
	Income (loss) before income taxes	12,358		181		2,860		(19,785	)	(4,386		)
	Depreciation and amortization	2,763		1,854		282		845		5,744
	Capital expenditures	2,134		1,211		80		—		3,425

Civil_Investigative_Demand

Civil Investigative Demand	6 Months Ended
	Jun. 30, 2014
Civil Investigative Demand	'
Civil Investigative Demand	'
	8.              Civil Investigative Demand
	On August 25, 2011, the Company received a Civil Investigative Demand (“CID”) issued by the U.S. Department of Justice, Western District of Washington. The CID states that it was issued as part of an investigation under the Federal False Claims Act and sought documents for the period January 1, 2007 through the date of the CID. The CID indicates that the investigation concerns allegations that the Company may have used inappropriate diagnosis codes when submitting claims for payment to Medicare for its real-time, MCOT™ services.  During the second quarter of 2014, the Company reached an agreement in principle for a potential settlement; however, the pending settlement is subject to satisfactory negotiation and completion of a settlement agreement.  As result, in addition to the $3,100 recorded in the first quarter of 2014, the Company recorded an additional non-operating charge of $3,300, reflecting an estimated total cash settlement amount of $6,400.  This reserve was recorded to Interest and other loss, net in the consolidated statements of operations and is included in Accrued liabilities on the balance sheet.  Additionally, the Company has incurred $1,720 in related legal and consulting expenses to date.
	The final outcome of any current or future litigation or governmental or internal investigations, including the potential settlement described above, cannot be accurately predicted, nor can the Company predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. The Company records accruals for such contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
Unaudited Interim Financial Data	'
	Unaudited Interim Financial Data
	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and the requirements of Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations and cash flows.  In the opinion of management, these consolidated financial statements reflect all adjustments which are of a normal recurring nature and necessary for a fair presentation of BioTelemetry, Inc.’s (the “Company” or “BioTelemetry”) financial position as of June 30, 2014 and December 31, 2013, the results of operations for the three and six months ended June 30, 2014 and 2013, and cash flows for the six months ended June 30, 2014 and 2013.  The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2014 and 2013 are unaudited. The results for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for any future period.
Net Loss	'
	Net Loss
	The Company computes net loss per share in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 260, Earnings Per Share.  The following summarizes the potential outstanding common stock of the Company at June 30, 2014 and 2013:
		June 30, 2014		June 30, 2013
	Employee stock purchase plan estimated share options outstanding	88,094		50,477
	Common stock options and restricted stock units outstanding	4,322,496		4,129,523
	Common stock options and restricted stock units available for grant	3,105,541		2,429,098
	Common stock	26,421,886		25,549,762
	Total	33,938,017		32,158,860
	Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common shares, including stock options and warrants, as applicable.
	The following table presents the calculation of basic and diluted net loss per share:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
		(in thousands, except share and per share amounts)
	Numerator:
	Net loss	$	(3,988	)	$	(2,299	)	$	(8,110	)	$	(4,386	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share	26,434,047			25,537,358			26,272,436			25,370,164
	Basic and diluted net loss per share	$	(0.15	)	$	(0.09	)	$	(0.31	)	$	(0.17	)
	If the outstanding vested options or restricted stock units were exercised or converted into common stock, the result would be anti-dilutive for the three and six months ended June 30, 2014 and 2013. Accordingly, basic and diluted net loss per share are the same for the three and six months ended June 30, 2014 and 2013.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For our long-term debt, based on the borrowing rates currently available to us, the carrying value also approximates fair value as of June 30, 2014 (classified as Level 2).  We did not have any Level 3 assets or liabilities for the periods ended June 30, 2014 and December 31, 2013.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable related to the Patient Services segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. The Company records allowance for doubtful accounts based on the aging of receivables using historical payor specific data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the healthcare industry and third party reimbursement, it is possible that the Company’s estimates of collectability could change, which could have a material impact on the Company’s operations and cash flows.
	Accounts receivable related to the Product and Research Services segments are recorded at the time revenue is recognized, or when the services or products are billable, net of discounts. The Company estimates allowance for doubtful accounts on a specific account basis, and considers several factors in its analysis including customer specific information and aging of the account.
	The Company writes off receivables when the likelihood for collection is remote and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect.  The Company performs write-offs on a monthly basis.  In the Patient Services segment, the Company wrote off $2,851 and $4,637 of receivables for the six months ended June 30, 2014 and 2013, respectively.  The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts.  There were no material write-offs in the Product and Research Services segments.  For the three and six months ended June 30, 2014, the Company recorded bad debt expense of $2,745 and $5,104, respectively.  For the three and six months ended June 30, 2013, the Company recorded bad debt expense of $1,967 and $4,434, respectively.
Inventory	'
	Inventory
	Inventory consists of the following:
		June 30,			December 31,
		2014			2013
	Raw materials and supplies	$	2,686		$	2,404
	Finished goods	284			150
	Total inventories	$	2,970		$	2,554
	Inventories, which include purchased parts, materials, direct labor and applied manufacturing overhead, are stated at the lower of cost or net realizable value, with cost determined by use of the first-in, first-out method.
Goodwill	'
	Goodwill
	Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other, goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units’ goodwill. If the carrying value of the reporting units’ goodwill exceeds its implied fair value, an impairment loss equal to the difference is recorded.
	For the purpose of performing its goodwill impairment analysis, the Company considers its business to be comprised of three reporting units: Patient Services, Product and Research Services. The Company calculates the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes the Company’s market data as well as market data from publicly traded companies that are similar to the Company. There are inherent uncertainties related to these factors and the judgment applied in the analysis. The Company believes that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of its reporting units.
Stock-Based Compensation	'
	Stock-Based Compensation
	ASC 718, Compensation — Stock Compensation, addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measure the cost of equity-based service awards based on the grant-date fair value of the award and recognize the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measure the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. The Company accounts for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees.
	As a result of stock-based compensation expense incurred, the Company’s loss before income taxes was increased by $965 and $1,968, respectively, during the three and six months ended June 30, 2014.  As a result of stock-based compensation expense incurred, the Company’s loss before income taxes was increased by $1,011 and $1,711 during the three and six months ended June 30, 2013, respectively.  For the three and six months ended June 30, 2014, the impact of stock-based compensation expense on basic and diluted earnings per share was $(0.04) and $(0.07).  For the three and six months ended June 30, 2013, the impact of stock-based compensation expense on basic and diluted earnings per share was $(0.04) and $(0.07).
	The Company estimates the fair value of its share-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of the Company’s stock and the expected term of the award. For the six months ended June 30, 2014 and 2013, the Company based the estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that stock-based awards granted are expected to be outstanding. Other assumptions used in the Black-Scholes option valuation model include the risk-free interest rate and expected dividend yield. The risk-free interest rate for periods pertaining to the contractual life of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. The Company has never paid, and does not expect to pay, dividends in the foreseeable future.
	The Company utilized the Black-Scholes valuation model for estimating the fair value of stock options granted using the following weighted average assumptions:
		Six months Ended
		June 30,
		2014		2013
	Expected dividend yield	0	%	0	%
	Expected volatility	62	%	60	%
	Risk-free interest rate	1.85	%	1.28	%
	Expected life	6.46		6.75
	Based on the Company’s historical experience of options that cancel before becoming fully vested, the Company has assumed an annualized forfeiture rate of 15% for all options. Under the true-up provision of ASC 718, the Company will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
	Based on the above assumptions, the per share weighted average fair value of the options granted under the stock option plan for the six months ended June 30, 2014 and 2013 was $4.96 and $1.47, respectively.
	The following table summarizes activity under all stock award plans from December 31, 2013 through June 30, 2014:
				Options Outstanding
		Shares				Weighted
		Available		Number		Average
		for Grant		of Shares		Exercise Price
	Balance — December 31, 2013	2,404,498		3,993,590		$	5.25
	Additional options available for grant	1,291,200		—		—
	Granted	(623,650	)	623,650		8.38
	Canceled	68,044		(68,044	)	3.59
	Exercised	—		(192,580	)	4.52
	Balance — March 31, 2014	3,140,092		4,356,616		5.78
	Granted	(125,985	)	125,985		8.2
	Canceled	91,434		(91,434	)	4.51
	Exercised	—		(68,671	)	4.55
	Balance — June 30, 2014	3,105,541		4,322,496		$	5.91
	The Employee Stock Option (ESOP) Plans have an automatic increase in the shares available for grant every January the plans are active. The increase in the shares available for grant under the ESOP plan is equal to 4% of the total shares outstanding at December 31, 2013.
	Additional information regarding options outstanding is as follows:
		June 30, 2014			June 30, 2013
	Range of exercise prices (per option)	$	0.70 - $31.18		$	0.70 - $31.18
	Weighted average remaining contractual life (years)	7.31			7.77
	Employee Stock Purchase Plan
	In 2014, 169,610 shares were purchased in accordance with the Employee Stock Purchase Plan (ESPP). Net proceeds to the Company from the issuance of shares of common stock under the ESPP for the six months ended June 30, 2014 were $397. In January 2014, the number of shares available for grant was increased by 258,240, per the ESPP documents. At June 30, 2014, approximately 606,086 shares remain available for purchase under the ESPP.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition.  The new standard will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which the company expects to receive in exchange for those goods or services.  The standard also requires new, expanded disclosures regarding revenue recognition and is effective for the annual reporting periods beginning after December 15, 2016.  The Company is currently evaluating the impact the adoption of this standard will have on the consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
Summary of potential outstanding common stock	'
		June 30, 2014		June 30, 2013
	Employee stock purchase plan estimated share options outstanding	88,094		50,477
	Common stock options and restricted stock units outstanding	4,322,496		4,129,523
	Common stock options and restricted stock units available for grant	3,105,541		2,429,098
	Common stock	26,421,886		25,549,762
	Total	33,938,017		32,158,860
Schedule of calculation of basic and diluted net loss per share	'
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
		(in thousands, except share and per share amounts)
	Numerator:
	Net loss	$	(3,988	)	$	(2,299	)	$	(8,110	)	$	(4,386	)
	Denominator:
	Weighted average shares used in computing basic and diluted net loss per share	26,434,047			25,537,358			26,272,436			25,370,164
	Basic and diluted net loss per share	$	(0.15	)	$	(0.09	)	$	(0.31	)	$	(0.17	)
Schedule of inventory	'
		June 30,			December 31,
		2014			2013
	Raw materials and supplies	$	2,686		$	2,404
	Finished goods	284			150
	Total inventories	$	2,970		$	2,554
Schedule of the weighted average assumptions used in estimating the fair value of stock options granted	'
		Six months Ended
		June 30,
		2014		2013
	Expected dividend yield	0	%	0	%
	Expected volatility	62	%	60	%
	Risk-free interest rate	1.85	%	1.28	%
	Expected life	6.46		6.75
Schedule of option activity under all stock award plans	'
				Options Outstanding
		Shares				Weighted
		Available		Number		Average
		for Grant		of Shares		Exercise Price
	Balance — December 31, 2013	2,404,498		3,993,590		$	5.25
	Additional options available for grant	1,291,200		—		—
	Granted	(623,650	)	623,650		8.38
	Canceled	68,044		(68,044	)	3.59
	Exercised	—		(192,580	)	4.52
	Balance — March 31, 2014	3,140,092		4,356,616		5.78
	Granted	(125,985	)	125,985		8.2
	Canceled	91,434		(91,434	)	4.51
	Exercised	—		(68,671	)	4.55
	Balance — June 30, 2014	3,105,541		4,322,496		$	5.91
Summary of additional information regarding options outstanding	'
		June 30, 2014			June 30, 2013
	Range of exercise prices (per option)	$	0.70 - $31.18		$	0.70 - $31.18
	Weighted average remaining contractual life (years)	7.31			7.77

Business_Combination_Tables

Business Combination (Tables)	6 Months Ended
	Jun. 30, 2014
Mednet	'
Business Acquisition	'
Schedule of unaudited pro forma information representing combined results of operations as if the acquisition had occurred at the beginning of the periods presented	'
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Revenue	$	42,650		$	38,831		$	83,310		$	78,656
	Net Loss	$	(3,988	)	$	(3,396	)	$	(6,331	)	$	(3,155	)
	Net loss per common share:
	Basic and Diluted	$	(0.15	)	$	(0.13	)	$	(0.24	)	$	(0.12	)
	Weighted average number of shares:
	Basic	26,434,047			26,815,245			26,272,436			25,634,007
Mednet | CardioNet	'
Business Acquisition	'
Schedule of the preliminary fair value estimates of assets acquired and liabilities assumed	'
	Fair value of assets acquired:
	Cash and cash equivalents	$	(199	)
	Accounts receivable	3,879
	Prepaid expenses and other current assets	355
	Property and equipment	4,400
	Goodwill	9,261
	Intangible assets	8,490
	Other assets	73
	Total assets acquired	26,259
	Liabilities assumed:
	Accounts payable	5,927
	Accrued expenses	994
	Other liabilities	3,413
	Long-term debt, capital leases, note payable and related interest	9,720
	Total liabilities assumed	20,054
	Net assets acquired	$	6,205
Schedule of estimated allocation of finite-lived and indefinite-lived intangible assets	'
		Estimated		Fair Value
		Useful Life
		(Years)
	Customer relationships	13		$	5,800
	Internally Developed Software	5		1,600
	Covenants not to compete	5		390
	Indefinite-lived trade name			700
	Total intangible assets			$	8,490
BMS | CardioNet	'
Business Acquisition	'
Schedule of the preliminary fair value estimates of assets acquired and liabilities assumed	'
	Fair value of assets acquired:
	Property and equipment	$	2,731
	Goodwill	3,559
	Intangible assets	2,360
	Net assets acquired	$	8,650
Schedule of estimated allocation of finite-lived intangible assets	'
		Estimated		Fair Value
		Useful Life
		(Years)
	Customer relationships	15		$	2,100
	Covenants not to compete	7		260
	Total intangible assets			$	2,360

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets	'
Schedule of changes in the carrying amounts of goodwill by segment	'
		Reporting Segment
		Patient			Research			Product		Total
		Services			Services
	Balance at December 31, 2013	$	1,577		$	11,735		$	3,157	$	16,469
	Goodwill acquired during the year	12,820			214			—		13,034
	Balance at June 30, 2014	$	14,397		$	11,949		$	3,157	$	29,503
Schedule of gross carrying amounts and accumulated amortization of the entity's intangible assets	'
		Estimated		June 30,			December 31,
		Useful Life		2014			2013
		(Years)
	Customer relationships	5 - 15		$	10,000		$	2,100
	Proprietary technology	5-Mar		5,600			4,000
	Signed backlog	1 - 4		3,160			2,800
	Unsigned backlog	4		600			600
	Covenants not to compete	7-May		1,010			360
	Total intangible assets, gross			20,370			9,860
	Customer relationships accumulated amortization			(1,111		)	(722		)
	Proprietary technology accumulated amortization			(2,649		)	(1,902		)
	Signed backlog accumulated amortization			(1,671		)	(1,400		)
	Unsigned backlog accumulated amortization			(275		)	(200		)
	Covenants not to compete accumulated amortization			(201		)	(124		)
	Total accumulated amortization			(5,907		)	(4,348		)
	Indefinite-lived trade name			2,500			1,800
	Total intangible assets, net			$	16,963		$	7,312
Summary of estimated amortization expense for the next five years	'
	Remainder of 2014	$	1,725
	2015	3,095
	2016	1,999
	2017	1,295
	2018	1,156
	2019	791
	Thereafter	4,402
	Total	$	14,463

Integration_Restructuring_and_1

Integration, Restructuring and Other Charges (Tables)	6 Months Ended
	Jun. 30, 2014
Integration, Restructuring and Other Charges	'
Summary of expenses related to restructuring, integration and other activities	'
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Legal fees	$	285	$	2,144	$	2,734	$	2,682
	Severance and employee related costs	593		187		755		740
	Professional fees	122		210		491		321
	Total	$	1,000	$	2,541	$	3,980	$	3,743

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Information	'
Summary of financial information concerning the entity's reportable segments	'
	For the three months ended:
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2014
	Revenues	$	34,160	$	5,245	$	3,245	—		$	42,650
	Intersegment revenues	—		—		1,778		(1,778	)	—
	Income (loss) before income taxes	6,472		233		1,512		(12,205	)	(3,988		)
	Depreciation and amortization	2,124		910		130		78		3,242
	Capital expenditures	3,442		271		38		—		3,751
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2013
	Revenues	$	24,910	$	5,252	$	1,942	—		$	32,104
	Intersegment revenues	—		—		1,671		(1,671	)	—
	Income (loss) before income taxes	6,675		328		1,470		(10,772	)	(2,299		)
	Depreciation and amortization	1,463		848		139		286		2,736
	Capital expenditures	1,190		377		19		—		1,586
	For the six months ended:
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2014
	Revenues	$	63,454	$	10,085	$	6,273	—		$	79,812
	Intersegment revenues	—		—		4,815		(4,815	)	—
	Income (loss) before income taxes	11,978		19		3,590		(26,542	)	(10,955		)
	Depreciation and amortization	3,695		1,794		263		243		5,995
	Capital expenditures	6,843		675		92		—		7,610
		Patient		Research		Product		Corporate		Consolidated
		Services		Services				and Other
	June 30, 2013
	Revenues	$	49,615	$	10,124	$	4,783	—		$	64,522
	Intersegment revenues	—		—		2,744		(2,744	)	—
	Income (loss) before income taxes	12,358		181		2,860		(19,785	)	(4,386		)
	Depreciation and amortization	2,763		1,854		282		845		5,744
	Capital expenditures	2,134		1,211		80		—		3,425

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Potential outstanding common stock	'	'	'	'	'
Employee stock purchase plan estimated share options outstanding (in shares)	88,094	50,477	88,094	50,477	'
Common stock options and restricted stock units outstanding (in shares)	4,322,496	4,129,523	4,322,496	4,129,523	'
Common stock options and restricted stock units available for grant (in shares)	3,105,541	2,429,098	3,105,541	2,429,098	'
Common stock (in shares)	26,421,886	25,549,762	26,421,886	25,549,762	25,812,754
Total (in shares)	33,938,017	32,158,860	33,938,017	32,158,860	'
Calculation of basic and diluted net loss per share	'	'	'	'	'
Numerator: Net loss (in dollars)	($3,988)	($2,299)	($8,110)	($4,386)	'
Denominator: Weighted average shares used in computing basic and diluted net loss per share	26,434,047	25,537,358	26,272,436	25,370,164	'
Basic and diluted net loss per share (in dollars per share)	($0.15)	($0.09)	($0.31)	($0.17)	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accounts receivable	'	'	'	'
Bad debt expense	$2,745	$1,967	$5,104	$4,434
Patient services segment	'	'	'	'
Accounts receivable	'	'	'	'
Write-off of receivables	'	'	$2,851	$4,637

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Jun. 30, 2013
			segment			Stock options	Stock options	Stock options	Stock options
Inventory	'	'	'	'	'	'	'	'	'
Raw materials and supplies	$2,686	'	$2,686	'	$2,404	'	'	'	'
Finished goods	284	'	284	'	150	'	'	'	'
Total inventories	2,970	'	2,970	'	2,554	'	'	'	'
Goodwill	'	'	'	'	'	'	'	'	'
Number of reporting units	'	'	3	'	'	'	'	'	'
Stock-based compensation	'	'	'	'	'	'	'	'	'
Stock-based compensation (in dollars)	$965	$1,011	$1,968	$1,711	'	'	'	'	'
Impact of stock-based compensation expense on basic and diluted earnings per share (in dollars per share)	($0.04)	($0.04)	($0.07)	($0.07)	'	'	'	'	'
Assumptions used for estimating the fair value of stock options granted	'	'	'	'	'	'	'	'	'
Expected dividend yield (as a percent)	'	'	0.00%	0.00%	'	'	'	'	'
Expected volatility (as a percent)	'	'	62.00%	60.00%	'	'	'	'	'
Risk-free interest rate (as a percent)	'	'	1.85%	1.28%	'	'	'	'	'
Expected life	'	'	'6 years 5 months 16 days	'6 years 9 months	'	'	'	'	'
Additional disclosures	'	'	'	'	'	'	'	'	'
Annualized forfeiture rate (as a percent)	'	'	'	'	'	15.00%	'	15.00%	'
Weighted average fair value of the options granted (in dollars per share)	'	'	'	'	'	'	'	$4.96	$1.47
Shares Available for Grant	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period (in shares)	'	'	'	'	'	3,140,092	2,404,498	2,404,498	'
Additional options available for grant (in shares)	'	'	'	'	'	'	1,291,200	'	'
Granted (in shares)	'	'	'	'	'	-125,985	-623,650	'	'
Canceled (in shares)	'	'	'	'	'	91,434	68,044	'	'
Balance at the end of the period (in shares)	3,105,541	2,429,098	3,105,541	2,429,098	'	3,105,541	3,140,092	3,105,541	'
Number of Shares	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period (in shares)	'	'	'	'	'	4,356,616	3,993,590	3,993,590	'
Granted (in shares)	'	'	'	'	'	125,985	623,650	'	'
Canceled (in shares)	'	'	'	'	'	-91,434	-68,044	'	'
Exercised (in shares)	'	'	'	'	'	-68,671	-192,580	'	'
Balance at the end of the period (in shares)	'	'	'	'	'	4,322,496	4,356,616	4,322,496	'
Weighted Average Exercise Price	'	'	'	'	'	'	'	'	'
Balance at the beginning of the period (in dollars per share)	'	'	'	'	'	$5.78	$5.25	$5.25	'
Granted (in dollars per share)	'	'	'	'	'	$8.20	$8.83	'	'
Canceled (in dollars per share)	'	'	'	'	'	$4.51	$3.59	'	'
Exercised (in dollars per share)	'	'	'	'	'	$4.55	$4.52	'	'
Balance at the end of the period (in dollars per share)	'	'	'	'	'	$5.91	$5.78	$5.91	'
ESOP shares	'	'	'	'	'	'	'	'	'
Increase in shares available for grant under the ESOP plan as a percentage of total shares outstanding	'	'	'	'	4.00%	'	'	'	'

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (Stock option plan, USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Stock option plan	'	'
Additional information regarding options outstanding	'	'
Range of exercise prices, low end of range (in dollars per share)	$0.70	$0.70
Range of exercise prices, high end of range (in dollars per share)	$31.18	$31.18
Weighted average remaining contractual life	'7 years 3 months 22 days	'7 years 9 months 7 days

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 5) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jan. 31, 2014	Jun. 30, 2014
In Thousands, except Share data, unless otherwise specified			Employee Stock Purchase Plan	Employee Stock Purchase Plan
Employee stock purchase plan	'	'	'	'
Common stock purchased (in shares)	'	'	'	169,610
Net proceeds from the issuance of shares of common stock (in dollars)	'	'	'	$397
Increase in number of shares available for grant	'	'	258,240	'
Number of remaining shares available for purchase	3,105,541	2,429,098	'	606,086

Business_Combination_Details

Business Combination (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

In Thousands, except Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jan. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mednet

Mednet

Mednet

Mednet

Mednet

Mednet

Mednet

Mednet

Mednet

Mednet

CardioNet

CardioNet

CardioNet

CardioNet

CardioNet

CardioNet

Indefinite-lived trade name

Customer relationships

Internally Developed Software

Covenants not to compete

Business Acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase consideration in cash

'

'

'

'

'

'

'

'

'

$5,500

'

'

'

'

'

Number of shares of common stock issued for acquisition

'

'

'

'

'

'

'

'

'

96,649

'

'

'

'

'

Value of common stock issued for acquisition at closing

'

'

'

'

'

'

'

'

'

705

'

'

'

'

'

Fair value of assets acquired:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

'

'

'

'

'

'

'

'

'

-199

'

'

'

'

Accounts receivable

'

'

'

'

'

'

'

'

'

'

3,879

'

'

'

'

Prepaid expenses and other current assets

'

'

'

'

'

'

'

'

'

'

355

'

'

'

'

Property and equipment

'

'

'

'

'

'

'

'

'

'

4,400

'

'

'

'

Goodwill

29,503

'

29,503

'

16,469

'

'

'

'

'

9,261

'

'

'

'

Intangible assets

'

'

'

'

'

'

'

'

'

'

8,490

700

5,800

1,600

390

Other assets

'

'

'

'

'

'

'

'

'

'

73

'

'

'

'

Total assets acquired

'

'

'

'

'

'

'

'

'

'

26,259

'

'

'

'

Liabilities assumed:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts payable

'

'

'

'

'

'

'

'

'

'

5,927

'

'

'

'

Accrued expenses

'

'

'

'

'

'

'

'

'

'

994

'

'

'

'

Other liabilities

'

'

'

'

'

'

'

'

'

'

3,413

'

'

'

'

Long-term debt, capital leases, note payable and related interest

'

'

'

'

'

'

'

'

'

'

9,720

'

'

'

'

Total liabilities assumed

'

'

'

'

'

'

'

'

'

'

20,054

'

'

'

'

Net assets acquired

'

'

'

'

'

'

'

'

'

'

6,205

'

'

'

'

Estimated Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'13 years

'5 years

'5 years

Revenues

42,650

32,104

79,812

64,522

'

6,164

'

10,636

'

'

'

'

'

'

'

Pro Forma Information

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue

'

'

'

'

'

42,650

38,831

83,310

78,656

'

'

'

'

'

'

Net Loss

'

'

'

'

'

($3,988)

($3,396)

($6,331)

($3,155)

'

'

'

'

'

'

Net loss per common share: Basic and Diluted (in dollars per share)

'

'

'

'

'

($0.15)

($0.13)

($0.24)

($0.12)

'

'

'

'

'

'

Weighted average number of shares: Basic

'

'

'

'

'

26,434,047

26,815,245

26,272,436

25,634,007

'

'

'

'

'

'

Business_Combination_Details_2

Business Combination (Details 2) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Apr. 03, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
In Thousands, except Share data, unless otherwise specified			BMS	BMS	BMS	BMS
			CardioNet	CardioNet	CardioNet	CardioNet
					Customer relationships	Covenants not to compete
Business Acquisition	'	'	'	'	'	'
Purchase consideration in cash	'	'	$8,000	'	'	'
Number of common stock issued for acquisition (in shares)	'	'	62,859	'	'	'
Value of common stock issued for acquisition at closing	'	'	650	'	'	'
Fair value of assets acquired:	'	'	'	'	'	'
Property and equipment	'	'	'	2,731	'	'
Goodwill	29,503	16,469	'	3,559	'	'
Intangible assets	'	'	'	2,360	2,100	260
Net assets acquired	'	'	'	$8,650	'	'
Estimated Useful Life	'	'	'	'	'15 years	'7 years

Business_Combination_Details_3

Business Combination (Details 3) (RadCore, CardioCore, USD $)	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 03, 2014
RadCore | CardioCore	'
Business Acquisition	'
Purchase consideration in cash	$400
Number of common stock issued for acquisition (in shares)	22,513
Value of common stock issued for acquisition at closing	$200

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Changes in the carrying amounts of goodwill by segment	'	'
Balance at the beginning of the period	$16,469	'
Goodwill acquired during the year	13,034	'
Balance at the end of the period	29,503	16,469
Goodwill impairment charge	'	0
Patient Services	'	'
Changes in the carrying amounts of goodwill by segment	'	'
Balance at the beginning of the period	1,577	'
Goodwill acquired during the year	12,820	'
Balance at the end of the period	14,397	'
Research Services	'	'
Changes in the carrying amounts of goodwill by segment	'	'
Balance at the beginning of the period	11,735	'
Goodwill acquired during the year	214	'
Balance at the end of the period	11,949	'
Product	'	'
Changes in the carrying amounts of goodwill by segment	'	'
Balance at the end of the period	$3,157	$3,157

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details 2) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Finite lived intangible assets	'	'	'	'	'
Total intangible assets, gross	$20,370	'	$20,370	'	$9,860
Total accumulated amortization	-5,907	'	-5,907	'	-4,348
Indefinite-lived trade name	2,500	'	2,500	'	1,800
Total intangible assets, net	16,963	'	16,963	'	7,312
Estimated amortization expenses	'	'	'	'	'
Remainder of 2014	1,725	'	1,725	'	'
2015	3,095	'	3,095	'	'
2016	1,999	'	1,999	'	'
2017	1,295	'	1,295	'	'
2018	1,156	'	1,156	'	'
2019	791	'	791	'	'
Thereafter	4,402	'	4,402	'	'
Total	14,463	'	14,463	'	'
Amortization expense	871	574	1,559	1,193	'
Customer relationships	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Total intangible assets, gross	10,000	'	10,000	'	2,100
Total accumulated amortization	-1,111	'	-1,111	'	-722
Customer relationships | Minimum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'5 years	'	'
Customer relationships | Maximum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'15 years	'	'
Proprietary technology	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Total intangible assets, gross	5,600	'	5,600	'	4,000
Total accumulated amortization	-2,649	'	-2,649	'	-1,902
Proprietary technology | Minimum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'3 years	'	'
Proprietary technology | Maximum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'5 years	'	'
Signed backlog	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Total intangible assets, gross	3,160	'	3,160	'	2,800
Total accumulated amortization	-1,671	'	-1,671	'	-1,400
Signed backlog | Minimum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'1 year	'	'
Signed backlog | Maximum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'4 years	'	'
Unsigned backlog	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'4 years	'	'
Total intangible assets, gross	600	'	600	'	600
Total accumulated amortization	-275	'	-275	'	-200
Covenants not to compete	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Total intangible assets, gross	1,010	'	1,010	'	360
Total accumulated amortization	($201)	'	($201)	'	($124)
Covenants not to compete | Minimum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'5 years	'	'
Covenants not to compete | Maximum	'	'	'	'	'
Finite lived intangible assets	'	'	'	'	'
Estimated Useful Life	'	'	'7 years	'	'

Integration_Restructuring_and_2

Integration, Restructuring and Other Charges (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Integration, Restructuring and Other Charges	'	'	'	'
Legal fees	$285	$2,144	$2,734	$2,682
Severance and employee related costs	593	187	755	740
Professional fees	122	210	491	321
Total	$1,000	$2,541	$3,980	$3,743

Income_Taxes_Details

Income Taxes (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Income Taxes	'
Estimated annual effective tax rate (as a percent)	0.00%
Income Taxes	'
Income tax benefit	$2,845
Mednet	'
Income Taxes	'
Income tax benefit	$2,869

Credit_Agreement_Details

Credit Agreement (Details) (USD $)	Feb. 21, 2014	Apr. 03, 2014	Jun. 30, 2014	Aug. 29, 2012	Jun. 30, 2014	Feb. 21, 2014	Feb. 21, 2014	Feb. 21, 2014
In Thousands, unless otherwise specified	Mednet	Biomedical Systems acquisition	MidCap Financial, LLC	MidCap Financial, LLC	The Bancorp Bank	The Bancorp Bank	The Bancorp Bank	The Bancorp Bank
							April 2014 to March 2019	April 2019 to March 2024
Credit Agreement	'	'	'	'	'	'	'	'
Loan commitment	'	'	'	$15,000	'	'	'	'
Potential maximum loan commitment	'	'	'	30,000	'	'	'	'
Variable interest rate basis	'	'	'LIBOR	'	'	'	'	'
Spread on variable interest rate (as a percent)	'	'	4.75%	'	'	'	'	'
Unused line fee (as a percent)	'	'	0.50%	'	'	'	'	'
Loan termination fee (as a percent)	'	'	1.00%	'	'	'	'	'
Amount withdrawn for acquisition	'	8,000	'	'	'	'	'	'
Amount of outstanding balance on the credit agreement	'	'	8,000	'	9,636	'	'	'
Aggregate amount of agreement with The Bancorp Bank	'	'	'	'	'	9,830	'	'
Amount of assumed debt associated with acquisition	8,563	'	'	'	'	'	'	'
Interest rate (as a percent)	'	'	'	'	'	3.25%	'	'
Principal amount of monthly installment payments	'	'	'	'	'	'	$38	$75

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			segment
Segment Information	'	'	'	'
Number of operating segments	'	'	3	'
Segment information	'	'	'	'
Revenues	$42,650	$32,104	$79,812	$64,522
Income (loss) before income taxes	-3,988	-2,299	-10,955	-4,386
Depreciation and amortization	3,242	2,736	5,995	5,744
Capital expenditures	3,751	1,586	7,610	3,425
Patient Services	'	'	'	'
Segment information	'	'	'	'
Revenues	34,160	24,910	63,454	49,615
Capital expenditures	3,442	1,190	6,843	2,134
Research Services	'	'	'	'
Segment information	'	'	'	'
Revenues	5,245	5,252	10,085	10,124
Capital expenditures	271	377	675	1,211
Product	'	'	'	'
Segment information	'	'	'	'
Revenues	3,245	1,942	6,273	4,783
Capital expenditures	38	19	92	80
Operating segments | Patient Services	'	'	'	'
Segment information	'	'	'	'
Income (loss) before income taxes	6,472	6,675	11,978	12,358
Depreciation and amortization	2,124	1,463	3,695	2,763
Operating segments | Research Services	'	'	'	'
Segment information	'	'	'	'
Income (loss) before income taxes	233	328	19	181
Depreciation and amortization	910	848	1,794	1,854
Operating segments | Product	'	'	'	'
Segment information	'	'	'	'
Revenues	1,778	1,671	4,815	2,744
Income (loss) before income taxes	1,512	1,470	3,590	2,860
Depreciation and amortization	130	139	263	282
Corporate and Other	'	'	'	'
Segment information	'	'	'	'
Revenues	-1,778	-1,671	-4,815	-2,744
Income (loss) before income taxes	-12,205	-10,772	-26,542	-19,785
Depreciation and amortization	$78	$286	$243	$845

Civil_Investigative_Demand_Det

Civil Investigative Demand (Details) (Civil Investigative Demand, USD $)	3 Months Ended		31 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Mar. 31, 2014
Civil Investigative Demand	'	'	'
Civil Investigative Demand	'	'	'
Amount of non-operating charge	$3,300	$3,100	'
Estimated total cash settlement amount	6,400	'	'
Legal and consulting related expenses	'	'	$1,720